Sagar Lonial, MD on elotuzumab for mutliple myeloma patients

SOHO Saudi Arabia (DAY 5) - Dr Sagar LonialПодробнее

Innovative Therapy to Transform Myeloma Care & Enhance Patient OutcomesПодробнее

Cereblon modulators: a new class of myeloma therapy — Dr. Sagar Lonial | MCRT Webcast August 22Подробнее

Rise of antibody-based treatments in myelomaПодробнее

Treating Multiple Myeloma at First RelapseПодробнее

The antibody treatment landscape in myelomaПодробнее

ASCO 2017: Practice Impact of New Data and Recommendations for Multiple MyelomaПодробнее

Targeting Ocular Toxicity in Multiple MyelomaПодробнее

Innovative Management Models in Multiple MyelomaПодробнее

Dr. Lonial on the OPTIMISMM and ELOQUENT-3 Trials in MyelomaПодробнее

COMy 2016 Monoclonal Antibodies - Treatment of MM: LonialПодробнее

Elderly Patients With MyelomaПодробнее

Dr. Lonial Discusses Recent Updates in Multiple MyelomaПодробнее

Advancements in the Multiple Myeloma Treatment ParadigmПодробнее

Myeloma highlights from ASCO 2017Подробнее

Antibodies for Relapsed/ Refractory Multiple MyelomaПодробнее

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple MyelomaПодробнее

Developing Better, Novel Options for Patients With MyelomaПодробнее

Maintenance Therapy for Multiple MyelomaПодробнее

ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MMПодробнее